Skip to main content

Table 1 Studies included in the cumulative NMA for overall survival

From: Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

 

2008

2010

2012

2014

2016

RCTs: 100% HER2+

ALTTO

(Piccart-Gebhart 2016) [66]

BCIRG 006

(Slamon 2011) [44]

BCIRG 006

(Slamon 2011) [44]

BCIRG 006

(Slamon 2015) [21]

FNCLCC-PACS 04

(Spielmann 2009) [67]

FNCLCC-PACS 04

(Spielmann 2009) [67]

FNCLCC-PACS 04

(Spielmann 2009) [67]

FNCLCC-PACS 04

(Spielmann 2009) [67]

HannaH

(Jackisch 2016) [68]

HERA

(Smith 2007) [69]

HERA

(Smith 2007) [69]

HERA

(Gianni 2011) [19]

HERA

(Goldhirsch 2013) [64]

HERA

(Goldhirsch 2013) [64]

HORG

(Mavroudis 2015) [70]

NCCTG N9831 and NSABP B-31

(Romond 2005) [18]

NCCTG N9831 and NSABP B-31

(Romond 2005) [18]

NCCTG N9831 andNSABP B-31

(Perez 2011) [71]

NCCTG N9831 and NSABP B-31

(Perez 2014) [51]

NCCTG N9831 and NSABP B-31

(Perez 2014) [51]

NeoALTTO

(de Azambuja 2014) [72]

NeoALTTO

(de Azambuja 2014) [72]

NOAH

(Gianni 2010) [73]

NOAH

(Gianni 2010) [73]

NOAH

(Gianni 2014) [20]

NOAH

(Gianni 2014) [20]

NSABP B-41

(Robidoux 2016) [74]

PHARE

(Pivot 2013) [75]

PHARE

(Pivot 2013) [75]

RCTs: HER2+ subgroups

BCIRG 001

(Mackey 2013) [76]

BCIRG 001

(Mackey 2013) [76]

Boccardo 2010 [77]

Boccardo 2010 [77]

Boccardo 2010 [77]

Boccardo 2010 [77]

BR9601 and NEAT

(Earl 2012) [78]

BR9601 and NEAT

(Earl 2012) [78]

BR9601 and NEAT

(Earl 2012) [78]

Colozza 2005 [79]

Colozza 2005 [79]

Colozza 2005 [79]

Colozza 2005 [79]

Colozza 2005 [79]

Del Mastro 2015 [80]

E1199

(Sparano 2008) [81]

E1199

(Sparano 2008) [81]

E1199

(Sparano 2008) [81]

E1199

(Sparano 2008) [81]

E1199

(Sparano 2008) [81]

E2198

(Schneider 2015) [82]

FinHer

(Joensuu 2009) [83]

FinHer

(Joensuu 2009) [83]

FinHer

(Joensuu 2009) [83]

FinHer

(Joensuu 2009) [83]

FinXX

(Joensuu 2014) [84]

FinXX

(Joensuu 2014) [84]

GeparTrio

(von Minckwitz 2013) [85]

GeparTrio

(von Minckwitz 2013) [85]

GONO-MIG-1

(Del Mastro 2005) [86]

GONO-MIG-1

(Del Mastro 2005) [86]

GONO-MIG-1

(Del Mastro 2005) [86]

GONO-MIG-1

(Del Mastro 2005) [86]

GONO-MIG-1

(Del Mastro 2005) [86]

Miles 1999 [87]

Miles 1999 [87]

Miles 1999 [87]

Miles 1999 [87]

Miles 1999 [87]

Rocca 2014 [88]

Rocca 2014 [88]

TEACH

(Goss 2013) [89]

TEACH

(Goss 2013) [89]

 

UNICANCER-PACS-01

(Coudert 2012) [90]

UNICANCER-PACS-01

(Coudert 2012) [90]

UNICANCER-PACS-01

(Coudert 2012) [90]

Observational

Bayraktar 2012 [91]

Bayraktar 2012 [91]

Bayraktar 2012 [91]

Gonzalez-Angulo 2015 [92]

Seferina 2015 [93]

  1. HER2+ human epidermal growth factor receptor 2-positive, NMA network meta-analysis, OS overall survival, RCT randomized controlled trial